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Objective: Early coronary reperfusion of the ischemic myocardium is a desired
therapeutic goal to preserve myocardium. However, reperfusion itself contributes to
an additional myocardial injury (ie, reperfusion injury), which has been attributed to
neutrophil infiltration with subsequent release of proteases and oxygen-derived
radicals. We studied the effects of the serine protease inhibitor aprotinin (Trasylol)
on myocardial ischemia and reperfusion in a rat model.
Methods: The effects of aprotinin (5000 and 20,000 U/kg) were examined in vivo
in a rat model of regional myocardial ischemia (20 minutes) and long-term reper-
fusion (24 hours). Cardioprotecive effects were determined by means of measure-
ment of creatine kinase and myeloperoxidase activity within the myocardium, as
well as histochemical analysis.
Results: Aprotinin (20,000 U/kg) administrated 2 minutes before reperfusion sig-
nificantly attenuated myocardial injury expressed as creatine kinase washout com-
pared with that seen in vehicle-treated rats (65  25 vs 585  98 creatine kinase
difference in units per 100 mg, P  .01). Administration of 5000 U/kg of the
protease inhibitor resulted in partial inhibition of myocardial reperfusion injury.
Moreover, cardiac myeloperoxidase activity in the ischemic myocardium, a marker
of neutrophil accumulation, was significantly reduced after aprotinin treatment.
Histologic analysis of the reperfused myocardium demonstrated reduced polymor-
phonuclear leukocyte infiltration and reduced tissue injury. Furthermore, aprotinin
treatment resulted in decreased induction of cardiac myocyte apoptosis compared
with that seen in vehicle-treated rats.
Conclusions: Inhibition of serine proteases with aprotinin appears to be an effective
means of preserving ischemic myocardium from reperfusion injury, even after 24
hours of reperfusion. Aprotinin might exert cardioprotection through inhibition of
polymorphonuclear leukocyte–induced myocardial injury and inhibition of reperfu-
sion-induced apoptosis of cardiac myocytes.
Myocardial ischemia (MI) without reperfusion results in severecardiac dysfunction and myocyte necrosis. Therefore, earlyreperfusion of the ischemic myocardium is the desired goal.Evidence indicates that reperfusion itself contributes to anadditional myocardial injury in ischemic hearts (ie, reperfu-sion injury).1 This injury is preceded by loss of endothelial
function and accumulation of activated neutrophils into the ischemic-reperfused
From the Department of Cardiothoracic and
Vascular Surgerya and II Department of
Medicine-Cardiology,b Johannes Guten-
berg-University, Mainz, Germany.
Supported in part by grant Bu 819/3-1 of
Deutsche Forschungsgemeinschaft and
Robert Mueller-Foundation, Germany
(U.B., M.K., H.D., and M.B.).
Received for publication Oct 18, 2001; re-
visions requested Dec 10, 2001; revisions
received Jan 15, 2002; accepted for publi-
cation Feb 10, 2002.
Address for reprints: Michael Buerke, MD,
II Department of Medicine–Cardiology, Jo-
hannes Gutenberg-University, Langenbeck-
Str 1, D–55101 Mainz, Germany (E-mail:
buerke@mail.uni-mainz.de).
*These authors made equal contributions.
J Thorac Cardiovasc Surg 2002;124:942-9
Copyright © 2002 by The American Asso-
ciation for Thoracic Surgery
0022-5223/2002 $35.000 12/1/123703
doi:10.1067/mtc.2002.123703
Cardiopulmonary Support and Physiology Pruefer et al
942 The Journal of Thoracic and Cardiovascular Surgery ● November 2002
CSP
myocardium (ie, inflammatory injury). The inflammatory
component to ischemia-reperfusion injury can trigger both
necrosis and apoptosis, in which necrosis itself is an inflam-
matory-inducing process, compared with apoptosis, which
does not result in an inflammatory response. Several studies
have shown that neutrophils adhere to the vascular endo-
thelium, extravasate, and accumulate into ischemic-reper-
fused tissue.2,3 These activated neutrophils cause tissue in-
jury by releasing cytotoxic metabolites, including proteases
(ie, cathepsin G and elastase), oxygen–derived free radicals
(ie, superoxide and hydrogen peroxide), eicosanoids, and
cytokines.4 Several therapeutic strategies have been studied
in regard to limiting the inflammatory response after MI/R,
and recent attention has been focused on serine protease
inhibitors.
Serine proteases, such as elastase-related proteinases (ie,
cathepsin), use serine side chain hydroxyl groups to attack
and cleave peptide bonds in proteins.5 Cathepsin G and the
elastase-related proteases are the major neutral serine pro-
teases present in azurophil granules of neutrophils and
monocytes.4 However, the exact mechanism and biologic
relevance of many proteases is not precisely understood.
Exogenous serine protease inhibitors have been studied in
an attempt to limit polymorphonuclear neutrophil (PMN)–
mediated injury. Mulligan and colleagues6 demonstrated
that inhibition of elastase and cathepsin G significantly
reduces PMN-mediated lung injury.
The serine protease inhibitor aprotinin (Trasylol) belongs
to a group labeled as Kunitz protease inhibitors because of
its common Kunitz domain in its polypeptide structure.
Aprotinin has a molecular weight of 6512 d and is a natu-
rally occurring broad-spectrum serine proteinase inhibitor
obtained from bovine lungs. It consists of 58 amino acid
residues that are arranged in a single polypeptide chain
cross-linked by 3 disulfides. Aprotinin has also been re-
ported to inhibit neutrophil elastase release7 and superoxide
anion formation,8 suggesting an effect on neutrophil activa-
tion. Previous studies demonstrated cardioprotective effects
in acute MI without reperfusion9 or short-term reperfu-
sion.10 Other in vitro studies have demonstrated the impor-
tant role of PMN elastase in reperfusion of the ischemic
bowel,11 in elastase-mediated damage of cultured vascular
endothelial cells,12 and in isolated cardiac myocytes.13
However, the role of myocardial serine protease inhibitors
in myocardial ischemia and reperfusion (MI/R) and poten-
tial cardioprotective effects are still under investigation.
Therefore the primary objectives of the present study
were to determine (1) the in vivo effects of the exogenous
serine protease inhibitor aprotinin on myocardial tissue ne-
crosis, (2) neutrophil accumulation in the ischemic-reper-
fused myocardium, and (3) induction of postreperfusion
apoptosis in a well-established model of rat MI and long-
term reperfusion.
Materials and Methods
Experimental Protocol
Male Sprague-Dawley rats (225-250 g) were anesthetized with
ether before the operation. A skin incision was made over the left
thorax, and pectoral muscles were retracted to expose the ribs. A
purse-string suture was placed loosely through the skin and un-
derlying musculature to facilitate rapid closure of the chest wall. A
thoracotomy was performed at the level of the fifth intercostal
space. MI was produced by briefly exteriorizing the heart and
placing a 4-0 silk suture around the left coronary artery, approxi-
mately 2 to 3 mm from its origin, effectively occluding the vessel.
Because the rat has low coronary collateral circulation, this method
results in a uniform degree of myocardial injury. After the slipknot
was tied, the heart was replaced in the thoracic cavity; air was
evacuated from the thorax; the chest wall, muscles, and skin were
rapidly closed by using the previously placed purse-string sutures;
and the rats were allowed to breath spontaneously. These proce-
dures are routinely completed in less than 60 seconds. Left ven-
tricular free wall (LVFW) is subjected to severe ischemia. After 20
minutes of MI, the slipknot was released, initiating reperfusion of
the ischemic myocardium. Sham-operated control rats (sham MI)
underwent the same surgical procedures, except that the suture,
which was passed under the left coronary artery, was not tied.
After the surgical procedure, the rats were observed for 2 hours
and than placed in a cage for the remaining 24 hours (eg, reper-
fusion time).
Rats were randomly divided into 4 major groups, consisting of
the following: (1) sham MI rats receiving aprotinin (Trasylol;
Bayer, Leverkusen, Germany; 20,000 U/kg body weight; n  9);
(2) MI/R rats receiving vehicle (NaCl 0.9%, n  8); (3) MI/R rats
receiving 5000 U/kg aprotinin (n  10); and (4) MI/R rats receiv-
ing 20,000 U/kg aprotinin (n  9). Aprotinin or its vehicle were
administered by means of single intravenous bolus injection 2
minutes before reperfusion of the ischemic myocardium.
After 24 hours of reperfusion, rats were anesthetized with
pentobarbital sodium, and their hearts were excised and placed in
oxygenated Krebs-Henseleit (K-H) solution at 4°C and pH 7.4.
The K-H solution consisted of the following: NaCl, 118 mmol/L;
KCl, 4.75 mmol/L; CaCl2  2H2O, 2.54 mmol/L; KH2PO4, 1.19
mmol/L; NaHCO3, 12.5 mmol/L; and glucose, 10.0 mmol/L. Rats
showing major bleeding inside the thoracic cavity or ineffective
reperfusion (ie, persisting ligature) were excluded from the study.
All hearts were examined at the site of the ligature to obtain proper
reperfusion after regional ischemia. In detail, the hearts were
investigated with a stereomicroscope to determine whether the
ligature was loose and whether there was proper reperfusion. After
24 hours, the exclusion rate and mortality rate together were less
than 15%. The aorta, atrium, right ventricle, and adherent fat or
connective tissue were dissected from the left ventricle. The
LVFW (ischemic-reperfused myocardium) and interventricular
septum (IVS; nonischemic control myocardium) were separated
and homogenized in cold 0.25 mol/L sucrose containing 1 mmol/L
ethylenediamine tetraacetic acid (EDTA) and 1 mmol/L mercap-
toethanol with an Ultra-Turrax tissue homogenizer (Jahnke 
Kunkel, Staufen, Germany). Homogenates were centrifuged at
36,000g at 4°C for 30 minutes. The supernatants were decanted
and analyzed spectrophotometrically for myocardial creatine ki-
nase (CK) content and myeloperoxidase (MPO) activities.
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In additional sham rats (n  5) we determined the hemody-
namic parameters and white blood cell counts after aprotinin
administration. There were no significant changes in any of the
cardiovascular variables (heart rate and blood pressure) or any
significant changes in white blood cell counts measured in sham-
operated rats treated with 20,000 U/kg aprotinin bolus injection.
All experiments were approved by the University Animal Care
Committee.
Myocardial CK Analysis
The CK washout (or CK loss) from the injured left ventricle has
been shown to be a useful marker for myocyte injury after MI/
R.14,15 Lefer and colleagues15 showed that peak myocardial CK
loss occurred 24 hours after myocardial reperfusion. Thus we
compared myocardial CK activity between the ischemic-reper-
fused LVFW and the control nonischemic IVS. CK activity of
LVFW and septum was measured by using the method of Rosa-
lki.16 The supernatants of the homogenized myocardium (ie,
LVFW and septum) were incubated with adenosine diphosphate
and phosphocreatine (Sigma Chemical Co, Deisenhofen, Germa-
ny), and the change in absorbance was measured spectrophoto-
metrically at 340 nm. Myocardial CK loss after MI/R was calcu-
lated in each rat by subtracting CKLVFW from CKIVS and
expressed in international units per milligram of protein. The
protein concentration was determined by using the biuret method
of Gornall and colleagues.17
In additional rats (n  5) receiving vehicle, the above-de-
scribed procedures were performed, except that one half of the
LVFW was incubated with 20,000 U/kg aprotinin or an equal
volume of 0.9% NaCl to determine whether aprotinin altered the
CK assay. These values were not significantly different, indicating
that aprotinin had no direct effect on the CK assay. All assays were
measured without prior knowledge of the group of origin of each
rat.
Determination of Myocardial MPO Activity
The myocardial activity of MPO, an enzyme occurring virtually
exclusively in neutrophils, was determined by using the method of
Bradley and colleagues,18 as modified by Mullane and associ-
ates.19 Change in absorbance was measured spectrophotometri-
cally in the supernatants of homogenized myocardium (ie, LVFW
and IVS). One unit of MPO is defined as the quantity of enzyme
hydrolyzing 1 mmol of peroxide per minute at 25°C. The elevation
of the MPO activity in the LVFW was calculated by subtracting
MPOIVS from MPOLVFW and expressed as cardiac MPO differ-
ence (in units per 100 mg tissue weight.
In additional rats (n  4) receiving vehicle, the above-de-
scribed procedures were performed, except that one half of the
necrotic tissue was incubated with 20,000 U/kg aprotinin or an
equal volume of 0.9% NaCl to determine whether aprotinin altered
the MPO assay. These values were not significantly different,
indicating that aprotinin had no direct effect on the MPO assay. All
MPO determinations were made without prior knowledge concern-
ing the group of treatment of each rat.
Histologic Analysis of Neutrophil Infiltration and
Myocardial Tissue Injury
Rat hearts were removed at the end of the reperfusion period and
immediately cannulated through the aorta. The hearts were per-
fused for 2 minutes with K-H buffer (ie, until the heart was cleared
of blood). After the hearts were cleared of blood, perfusion was
switched to 4% paraformaldehyde in phosphate-buffered saline
(pH 7.4 at 4°C) for 5 minutes to perfusion fix the hearts. Full-
thickness slices of the myocardial tissue were fixed for 1.5 hours
at 4°C in 4% paraformaldehyde. After 1.5 hours, the slices were
dehydrated in a graded series of acetone (ie, 50%, 70%, 90%, and
100%) at 4°C. After dehydration, the sections were infiltrated with
methacrylate (Immunobed; Polyscience, Eppelheim, Germany) at
room temperature for 24 hours and subsequently embedded in
methacrylate at 4°C for 12 hours. Glass knives were used to cut
5-m-thick tissue sections. The tissue sections were placed on
Vectabond-coated slides (Vector Laboratories, Burlingame, Calif).
The sections were stained with Gill’s hematoxylin solution (Sigma
Co) and examined with a Zeiss microscope (Zeiss, Go¨ttingen,
Germany). The numbers of PMNs in 5 fields of each slide were
counted from each heart. Three rats were studied in each group.
In Situ Determination of Apoptosis in Ischemic
Reperfused Myocardium
Because reperfusion of ischemic myocardium results in necrotic
tissue injury, as well as cardiac myocyte apoptosis, we performed
in situ detection of myocardial apoptosis. Rats were subjected to
sham ischemia or 20 minutes of ischemia followed by 24 hours of
reperfusion and given either 20,000 U/kg aprotinin (n  5) or its
vehicle (n  5). At the end of reperfusion period, the hearts were
removed and perfused retrogradely with K-H buffer for 2 minutes.
Myocardium was perfused, fixed, embedded, and cut, as described
previously.
The presence of apoptosis in the ischemic-reperfused myocar-
dium was determined by means of direct immunoperoxidase de-
tection of digoxigenin-labeled genomic DNA in thin sections of
myocardium (ApopTag; Oncor, Gaithersburg, Md). Tissue sec-
tions were treated with trypsin and H2O2. Residues of digoxigenin
nucleotide were catalytically (1 hour at 37°C) added to the 3-OH
end of DNA by means of terminal deoxynucleotidyltransferase.
Incubation with the anti-digoxigenin antibody fragment was car-
ried out for 30 minutes at room temperature. Color development
was performed with a diaminobenzidine substrate/H2O2 solution
(Vector Laboratories). The sections were lightly counterstained
with hematoxylin and examined with a Zeiss light microscope
(Zeiss). Because sometimes necrotic myocytes express positive
TUNEL staining, we analyzed only myocytes that did not have the
typical signs of necrosis (ie, loss of cross-striations and loss of
membrane integrity). The percentage of immunolabeled nuclei of
myocytes (ie, apoptotic cells) was counted in random tissue sec-
tions as an index of occurrence of apoptosis. Myocytes were
analyzed in at least 10 separate fields for each tissue section. The
number of apoptotic myocytes (ie, peroxidase positive in the cell
nucleus) was counted for each field. The number of stained myo-
cytes was divided by the total number of myocytes and then
multiplied by 100 to determine the percentage of stained myocytes
as follows:
(Stained myocytes)/(Total myocytes) 100.
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Statistical Analysis
All values in Figures and text are presented as means  SEM (ie,
the mean of n independent experiments). All data were subjected
to analysis of variance, followed by the Fisher t test.
Results
Effect of Aprotinin on Myocardial Injury After
Ischemia and Reperfusion
To evaluate the extent of myocardial ischemic injury, we
measured CK activity in homogenates of nonischemic (ie,
IVS) or ischemic (ie, LVFW) myocardial tissue after 24
hours of reperfusion. Sham MI/R rats receiving either ve-
hicle or 20,000 U/kg aprotinin demonstrated no significant
difference in CK activity between IVS and LVFW, indicat-
ing that no myocyte necrosis occurred as a result of surgical
procedures (data not shown). However, rat hearts subjected
to coronary occlusion that were given only the vehicle
demonstrated significant loss of CK from the LVFW after
24 hours of reperfusion (P  .01 compared with sham MI
rats, Figure 1). In contrast, bolus injection of aprotinin
(either 5000 U/kg or 20,000 U/kg) 2 minutes before reper-
fusion significantly attenuated dose-dependent CK loss
from the ischemic-reperfused LVFW. These results clearly
indicate that administration of aprotinin prevents myocar-
dial tissue injury after reperfusion of the ischemic myocar-
dium in vivo.
Neutrophil Accumulation Into the Ischemic
Reperfused Myocardium
We measured MPO activity in the nonischemic septum
(IVS) and ischemic (LVFW) regions of the myocardium
and calculated the difference (LVFW IVS) between the 2
MPO values as an index of neutrophil accumulation. Sham-
operated control rats receiving 20,000 U/kg aprotinin (Fig-
ure 2) showed low and similar levels and differences of
MPO to those of sham MI/R rats given vehicle or aprotinin
(5000 U/kg; data not shown). In contrast, MI rats receiving
only the vehicle exhibited a marked increase in MPO ac-
tivity in the ischemic-reperfused LVFW. These data indi-
cate increased neutrophil accumulation into the reperfused
region of the myocardium. However, administration of 5000
and 20,000 U/kg aprotinin intravenously 2 minutes before
reperfusion significantly attenuated dose-dependent MPO
activity in the ischemic-reperfused myocardium. Similarly,
histologic analysis (Figure 3, A and B) of the ischemic-
reperfused myocardium confirmed the results of the bio-
chemical assay. These results indicate that the cardioprotec-
tive effects of aprotinin might be partially attributed to
inhibition of neutrophil accumulation into the ischemic-
reperfused myocardium.
Immunohistochemical Localization of Apoptosis After
Myocardial Ischemia and Reperfusion
The presence of apoptosis in the ischemic-reperfused myo-
cardium was determined by means of direct immunoperox-
idase detection of digoxigenin-labeled genomic DNA in
thin sections of myocardium. Nonischemic sections of heart
tissue or any section from sham MI hearts failed to demon-
strate any significant immunostaining. (ie, 3% of the
myocytes were stained; Figure 4). Similarly, immunohisto-
logic preparations, in which either the digoxigenin-dUTP
Figure 1. Effect of single administration of aprotinin on myocardial injury after reperfusion of ischemic myocardium.
CK activity is calculated as the difference between IVS and LVFW expressed in international units per 100 mg. All
values are means  SEM.
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(deoxy-uridinetriphosphate) or the antibody peroxidase con-
jugate was replaced with nonimmune serum, failed to ex-
hibit any labeling of myocardial or other cell types. In
contrast to these controls, apoptosis was clearly evident in
ischemic myocardial sections obtained from untreated isch-
emic-reperfused hearts (ie, 29%  4% positive stained
myoctyes; P  .01 compared with sham MI rats). Brown
reaction product was present in nuclei of apoptotic cells.
Apoptosis occurred in single myocytes, and there was no
close relation to infiltrating neutrophils in close proximity to
the coronary vasculature detectable. Intense immunostain-
ing was evident in myocytes, as well as in infiltrating
leukocytes. Ischemic-reperfused myocardium of rats treated
with 20,000 U/kg aprotinin demonstrated a marked reduc-
tion of immunostaining (ie, 15%  3%; P  .05 compared
with rats receiving only vehicle), indicating reduced occur-
rence of apoptosis after aprotinin treatment (Figure 3, C and
D). In myocardium of vehicle-treated animals, we also
observed infiltrating leukocytes undergoing apoptosis. Be-
cause aprotinin treatment reduced leukocyte accumulation,
the number of apoptotic leukocytes was lower. These results
demonstrate that reperfusion of ischemic myocardium in-
duces cardiac myocyte apoptosis and that inhibition of
serine proteases with aprotinin appears to be an effective
inhibitor of cardiac myocyte apoptosis induction.
Discussion
Our results clearly demonstrate significant cardioprotective
activities of the serine protease inhibitor aprotinin after
reperfusion of ischemic myocardium. Aprotinin demon-
strated cardioprotective effects in PMN-mediated tissue
damage and cardiac myocyte apoptosis in a model of car-
diac ischemia and long-term reperfusion in vivo. The car-
dioprotection exerted by aprotinin was characterized by
profound reduction of myocardial necrosis, significant inhi-
bition of PMN accumulation into the reperfused myocar-
dium, and diminished induction of cardiac myocyte apopto-
sis compared with that seen in rats given only the vehicle.
The cardioprotective effects can be partially attributed to
inhibition of complement activation and beneficial effects
on the protease-mediated cascade initiated by PMN activa-
tion, resulting in inhibition of leukocyte accumulation.
PMNs play a major role in endothelial injury of coronary
vessels, as well as in the propagation of myocardial necro-
sis. This is consistent with previous experimental findings
obtained in other species.20,21 Neutrophils might plug cap-
illaries and thus contribute to the no-reflow phenomenon
after reperfusion, thus exacerbating reperfusion-induced
myocardial necrosis. Neutrophils that adhere to the vascular
endothelium are subsequently activated and release cyto-
toxic metabolites, such as oxygen free radicals, proteolytic
enzymes, and cytokines.4 These mediators might further
lead to coronary endothelial injury, disruption of the sub-
endothelial basement membrane, and subsequent PMN ex-
travasation and myocardial necrosis.2,3
The reduction in tissue injury (ie, loss of CK) exerted by
aprotinin cannot be attributed to hemodynamic effects be-
cause bolus injection did not alter hemodynamic parame-
ters. Variations in collateral flow in the ischemic myocar-
dium as the cause of the cardioprotective effects are highly
Figure 2. Effect of single administration of aprotinin on neutrophil accumulation after reperfusion of ischemic
myocardium. Cardiac MPO as a marker for leukocyte infiltration is expressed as the difference between LVFW and
IVS activity. All values are means  SEM.
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unlikely because rat hearts have almost no coronary collat-
eral blood flow. In previous studies we have analyzed the
area at risk after LAD occlusion. In these experiments we
were able to demonstrate, with Evans blue exclusion, 60%
to 70% area at risk in the left ventricle. However, use of the
CK loss method might underestimate the cardioprotective
effects.
One important component of the myocardial salvage by
aprotinin might be due to its ability to reduce PMN accu-
mulation into the ischemic tissue because aprotinin treat-
ment significantly reduced tissue MPO activity in ischemic-
reperfused LWFW. Clearly, neutrophils are involved in
MI/R damage in our model because we observed significant
increases in MPO activities in vehicle-treated ischemic
myocardial tissue. The effects of aprotinin, however, cannot
be attributed to changes in circulating white blood cell
counts because bolus injection of aprotinin did not result in
a significant decrease in white blood cell counts. These data
eliminate the possibility that aprotinin administration in
vivo exerted leukopenic effects, a phenomenon known to be
cardioprotective in myocardial reperfusion injury.22
The precise mechanism of aprotinin-mediated attenua-
tion of PMN accumulation is unclear from the present study.
However, there are several possible mechanisms. The ex-
travasation process of circulating PMNs, mediated by en-
dothelial and leukocyte adhesion molecules, starts with
PMN rolling along the endothelial surface, followed by firm
adhesion, shape change, and transmigration across the ves-
sel wall into the interstitium.23 Activated neutrophils pro-
duce proinflammatory mediators, including neutral serine
proteases (eg, elastase or cathepsin G),24 tumor necrosis
factor- (TNF-), and oxygen-derived free radicals, which
serve to activate additional neutrophils.25 Hill and col-
leagues26 could demonstrate that aprotinin inhibits systemic
Figure 3. Photomicrographs of ischemic-reperfused (20 minutes of ischemia and 24 hours of reperfusion) myocar-
dium of rats treated either with vehicle (A) or 20,000 U/kg aprotinin (B). A, Ischemic-reperfused myocardial tissue
exhibits numerous leukocytes sequestered inside the coronary vasculature and transmigrated PMNs into the
myocardium. Cardiac myocytes are severely injured (ie, necrotic). B, Ischemic-reperfused myocardial tissue after
aprotinin treatment exhibits significant reduced PMN adhesion and PMN transmigration. In addition, there were
almost no visible signs of cardiac injury. (Original magnification 100.) C, Photomicrograph of rat heart tissue after
20 minutes of ischemia and 24 hours of reperfusion incubated with terminal deoxynucleotidyltransferase to add
residues of digoxigenin nucleotide catalytically to the 3-OH end of DNA and labeled with peroxidase substrate
solution. (Original magnification 400.) Brown reaction product is clearly present in nuclei of apoptotic myocytes
in vehicle-treated rats. D, Ischemic-reperfused myocardial tissue of rats treated with aprotinin demonstrated
remarkably diminished immunostaining, indicating reduced occurrence of myocardial apoptosis after aprotinin
treatment. (Original magnification 400.)
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TNF- release and subsequent neutrophil CD11b upregula-
tion. This is supported by the observation that TNF-–
stimulated release of platelet-activating factor and leukotri-
ene B4 can be inhibited by serpins and increased by
cathepsin G and human PMN elastase.27
In addition to these data, Rice and Weiss28 have demon-
strated that a serine protease inhibitor was effective in
reducing the degradation of fibronectin or elastin in vitro.
Therefore administration of an exogenous protease inhibitor
results in interruption of the protease-mediated inflamma-
tory cascade and is able to inhibit PMN-endothelial inter-
action and leukocyte infiltration. Similarly, in an in vitro
adhesion assay, aprotinin was able to reduce PMN adhesion
to thrombin-activated aortic endothelium (unpublished ob-
servation). This property of aprotinin might be one of the
key mechanisms by which aprotinin afforded cardioprotec-
tion in vivo.
Previous clinical studies have shown that aprotinin dem-
onstrated significant reduction of complement activation
during lifesaving ex vivo hemodialysis.29 Complement ac-
tivation plays an important role in myocardial reperfusion
injury. Complement activation after MI/R can induce P-
selectin and intercellular adhesion molecule expression, and
this facilitates neutrophil accumulation.30 In this regard
administration of aprotinin might be able to partially inhibit
complement activation after MI/R, with subsequent reduc-
tion of myocardial necrosis and PMN recruitment, because
aprotinin was able to inhibit complement-mediated sheep
cell hemolysis (data not shown).
Interestingly, complement activation after MI/R induces
cardiac myocyte apoptosis.31 Gottlieb and colleagues32 have
demonstrated, in a rabbit model, that MI/R induces apopto-
sis in reperfused myocardial myocytes and that this might
play an important role for delayed myocardial cell death.
Apoptosis occurred mainly after reperfusion of the ischemic
myocardium and seems to be a contributory mechanism to
reperfusion injury.33 Our results demonstrating end-labeling
of DNA in cardiac myocyte nuclei confirm and extend these
findings in a rat model of MI/R. Apoptosis represents a
control mechanism in morphogenesis and cell turnover of
cells in adult tissues. Apoptosis can be morphologically
characterized by cell shrinking, loss of cell contacts, and
aggregation of chromatin. Membrane-bound apoptotic bod-
ies are formed that contain intact cell organelles and con-
densed chromatin. These bodies are phagocytosed by mac-
rophages. Apoptosis can be triggered by cytokines, such as
TNF-, which can also contribute to reperfusion injury.34 In
this regard aprotinin demonstrated beneficial effects on
myocardial biochemical function through suppression of
TNF-.35 Recently, Buerke and colleagues36 were able to
demonstrate reduced myocyte apoptosis after insulin-like
growth factor I treatment in the same rat model of MI/R. In
our study aprotinin reduced the incidence of apoptosis in the
ischemic-reperfused myocardium. Because reperfusion-in-
duced apoptosis is independent of neutrophil accumulation
in the reperfused myocardium, the antiapoptotic actions of
aprotinin in the present experiments are presumably not
directly mediated by attenuation of PMN sequestration.
In conclusion, we have demonstrated that administration
of aprotinin attenuates both myocardial necrosis and apo-
Figure 4. Percentage of apoptotic cardiac myocytes in sham-operated MI rats, MI/R rats treated with vehicle (n 
5), and MI/R rats treated with 20,000 U/kg aprotinin (n  5). Apoptosis was determined with the TUNEL reaction.
Values are means  SEM.
Cardiopulmonary Support and Physiology Pruefer et al
948 The Journal of Thoracic and Cardiovascular Surgery ● November 2002
CSP
ptosis resulting from MI/R. These protective effects could
be at least partially attributed to reduced PMN accumulation
after aprotinin administration in the reperfused myocardium
and subsequent reduced cardiac necrosis. Aprotinin might
therefore have important anti-inflammatory effects in addi-
tion to its well-known antifibrinolytic effect, which is clin-
ically used for blood loss–lowering actions in cardiac sur-
gery and large general surgical procedures. Our observed
cardioprotective effects after aprotinin treatment might rep-
resent a strategy for primary prevention of tissue damage
mediated by ischemia and reperfusion or similar inflamma-
tory states.
Parts of these studies are included in the thesis of M. Khalil.
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